New ALS Treatment, AMX0035, Lacks Evidence of Benefit, FDA Panel Finds

The New York Times - Business:

With a 6-4 vote, the group of independent advisers to the agency narrowly concluded that results from another clinical trial are needed to assess whether the therapy, called AMX0035, can help patients.

Author: Pam Belluck

This post first appeared in The New York Times - Business. Read the original article.